在怀孕期间遗传性抗血缺乏症和静脉血栓形成 - - 一项回顾性多中心研究的结果
Ingunn Dybedal1, Nina Iversen2, Anne Flem Jacobsen3
1Department of Haematology, Oslo University Hospital, Oslo, Norway; Department of Pharmacology, Clinical Research Unit, Oslo University Hospital, Oslo, Norway.
Journal of thrombosis and haemostasis : JTH
|March 14, 2025
概括
患有抗血素 (AT) 缺乏症的女性在怀孕期间需要高剂量低分子量肝素 (LMWH) 进行预防. 抗血缩剂应在周围给药,以防止静脉血栓形成 (VT).
科学领域:
- 产科和妇科 产科和妇科
- 血液学 血液学 血液学
- 血栓形成研究研究
背景情况:
- 对于预防与怀孕相关的静脉血栓症 (VT) 在患有抗血 (AT) 缺乏症的女性中,最佳的抗凝药疗法仍未确定.
- 抗血素缺乏症在怀孕和产后期间对静脉瘤构成重大风险.
研究的目的:
- 确定最佳的低分子量肝素 (LMWH) 剂量,以预防与怀孕相关的AT缺乏症妇女的静脉瘤.
- 为了评估周产期抗血素 (AT) 缩剂在减少此患者群体中产后静脉血的疗效.
主要方法:
- 追溯分析115个怀孕在57名妇女的AT缺乏症.
- 1991年至2017年期间从丹麦,挪威和瑞典收集的数据.
- 亚特缺乏症的分类和LMWH剂量和VT事件的分析.
主要成果:
- 在高风险的AT缺乏妊娠中,LMWH剂量>12,500 IU/24 h与0.0的静脉瘤风险相关.
- 以前的体育训练是产前体育训练的重要风险因素.
- 产周期AT缩剂的使用可将静脉瘤发病率从25%降至1.5%在满期怀孕中.
结论:
- 从确诊的怀孕开始,建议使用高剂量的LMWH预防性治疗,用于高风险的AT缺乏怀孕,并有VT病史.
- 在分娩前服用AT缩剂对于预防分娩后静脉瘤至关重要.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
586
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
586
01:24Disorders of Hemostasis
674
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
674